Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Autolus Therapeutics plc

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LONDON AND GAITHERSBURG, MD., NOV. 03, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, ANNOUNCES THE ONLINE PUBLICATION OF FIVE ABSTRACTS SUBMITTED TO THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING, TO BE HELD DECEMBER 6-9, 2025, IN ORLANDO, FLORIDA.

AUTOLUS THERAPEUTICS TO PRESENT CLINICAL DATA UPDATES AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING 2025

LONDON & GAITHERSBURG, MD., OCT. 30, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), AN EARLY COMMERCIAL STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, TODAY ANNOUNCES THAT IT WILL RELEASE ITS THIRD QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS BEFORE OPEN OF U.S. MARKETS ON WEDNESDAY, NOVEMBER 12, 2025.

AUTOLUS THERAPEUTICS TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON NOVEMBER 12, 2025

DATA FROM THE PHASE 1 CARLYSLE STUDY IN SEVERE REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (SRSLE) SUGGESTS OBE-CEL IS WELL TOLERATED WITH NO ICANS OR HIGH-GRADE CRS; 50 MILLION CELL DOSE SELECTED FOR PHASE 2 PIVOTAL STUDY PRELIMINARY EFFICACY DATA DEMONSTRATE ACHIEVEMENT OF DEFINITION OF REMISSION IN SLE (DORIS) IN 83% OF PATIENTS AND COMPLETE RENAL RESPONSE (CRR) IN 50% OF PATIENTS; ALL RESPONSES AND REMISSIONS ARE ONGOING WITH NO EVIDENCE OF DISEASE ACTIVITY AT A MEDIAN FOLLOW-UP OF 8.9 MONTHS ALL PATIENTS HAD REFRACTORY LUPUS NEPHRITIS; 4/6 PATIENTS HAD SIGNIFICANTLY IMPAIRED KIDNEY FUNCTION PATIENTS RECEIVED NO OTHER LUPUS DIRECTED THERAPY; STEROIDS WERE TAPERED IN ALL PATIENTS TO 5MG BY MONTH SIX COMPANY REMAINS ON TRACK TO DOSE FIRST PATIENT IN PHASE 2 TRIAL IN LUPUS NEPHRITIS (LN) BY YEAR-END 2025 LONDON AND GAITHERSBURG, MD., OCT. 27, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, ANNOUNCES THAT FOLLOW-UP DATA FROM THE ONGOING CARLYSLE TRIAL, A PHASE 1 DOSE CONFIRMATION CLINICAL TRIAL OF OBE-CEL IN SEVERE REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (SRSLE), WILL BE PRESENTED DURING A POSTER SESSION AT THE AMERICAN COLLEGE OF RHEUMATOLOGY CONVERGENCE 2025.

AUTOLUS THERAPEUTICS PRESENTS CLINICAL DATA UPDATES AT THE AMERICAN COLLEGE OF RHEUMATOLOGY CONVERGENCE 2025

LONDON AND GAITHERSBURG, MD., OCT. 20, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, ANNOUNCES THAT THE FIRST PATIENT HAS BEEN DOSED IN ITS PHASE 1 BOBCAT TRIAL OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS (PMS).

AUTOLUS THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 TRIAL OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS

LONDON AND GAITHERSBURG, MD., OCT. 15, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES AND CANDIDATES, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS GRANTED STOCK OPTION AWARDS TO PURCHASE AN AGGREGATE OF 1,093,300 SHARES OF ITS COMMON STOCK TO 65 EMPLOYEES PURSUANT TO THE COMPANY'S 2025 INDUCEMENT PLAN.

AUTOLUS THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

AUTOLUS ANNOUNCES THE PUBLICATION OF AN ABSTRACT SUBMITTED TO THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2025, TO BE HELD OCTOBER 24-29, 2025.

AUTOLUS THERAPEUTICS TO PRESENT CLINICAL DATA UPDATE AT THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2025

COMPANY REPORTS Q2 2025 AUCATZYL NET PRODUCT REVENUE OF $20.9 MILLION AND $29.9 FOR THE FIRST SIX MONTHS OF 2025 COMPANY RECENTLY RECEIVED CONDITIONAL MARKETING AUTHORIZATION FROM U.K. MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA) AND CONDITIONAL EUROPEAN MARKETING AUTHORIZATION FROM THE EUROPEAN COMMISSION (EC) FOR AUCATZYL FOLLOW UP DATA FROM THE FELIX TRIAL DEMONSTRATING OBE-CEL'S POTENTIAL FOR LONG-TERM REMISSION IN R/R B-ALL PRESENTED AT THE 2025 EUROPEAN HEMATOLOGY ASSOCIATION (EHA) CONGRESS COMPANY IS ON TRACK TO INITIATE PHASE 2 PIVOTAL CLINICAL TRIAL IN LUPUS NEPHRITIS (LN) AND PHASE 1 CLINICAL TRIAL IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) BY YEAR-END 2025 CONFERENCE CALL TO BE HELD TODAY AT 08:30 AM EDT/13:30 PM BST: CONFERENCE CALL PARTICIPANTS SHOULD PRE-REGISTER USING THE LINK AT THE BOTTOM OF THIS PRESS RELEASE LONDON AND GAITHERSBURG, MD., AUG. 12, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, ANNOUNCES ITS OPERATIONAL AND FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025.

AUTOLUS THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES

LONDON AND GAITHERSBURG, MD., JULY 24, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), AN EARLY COMMERCIAL STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, TODAY ANNOUNCES THAT IT WILL RELEASE ITS SECOND QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS BEFORE OPEN OF U.S. MARKETS ON TUESDAY, AUGUST 12, 2025.

AUTOLUS THERAPEUTICS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON AUGUST 12, 2025

APPROVAL IS BASED ON FELIX CLINICAL TRIAL OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN ADULT PATIENTS WITH R/R B-ALL, DEMONSTRATING HIGH AND DURABLE RESPONSE RATES AND LOW TOXICITY EC APPROVAL FOLLOWS POSITIVE CHMP OPINION, MHRA CONDITIONAL MARKETING AUTHORIZATION AND FDA APPROVAL LONDON AND GAITHERSBURG, MD., JULY 21, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES AND CANDIDATES, ANNOUNCES TODAY THAT THE EUROPEAN COMMISSION (EC) HAS GRANTED MARKETING AUTHORIZATION FOR AUCATZYL (OBECABTAGENE AUTOLEUCEL OR OBE-CEL) FOR THE TREATMENT OF ADULT PATIENTS, 26+, WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL).

AUTOLUS THERAPEUTICS' CAR T THERAPY AUCATZYL (OBECABTAGENE AUTOLEUCEL) GRANTED EUROPEAN MARKETING AUTHORIZATION FOR ADULT PATIENTS (AGE 26 AND OLDER) WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL)

LONDON & GAITHERSBURG, MD., JULY 15, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES AND CANDIDATES, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS GRANTED STOCK OPTION AWARDS TO PURCHASE AN AGGREGATE OF 360,550 SHARES OF ITS COMMON STOCK TO 60 EMPLOYEES PURSUANT TO THE COMPANY'S 2025 INDUCEMENT PLAN. THE STOCK OPTIONS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE INDIVIDUAL BECOMING AN EMPLOYEE OF AUTOLUS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

MEDIAN DURATION OF RESPONSE IN FELIX STUDY NOW 42.6 MONTHS AFTER AN ADDITIONAL 11 MONTHS OF FOLLOW UP MORE THAN HALF OF PATIENTS STILL IN REMISSION AT 24 MONTHS 38% OF ONGOING RESPONDERS DID NOT RECEIVE ANY SUBSEQUENT THERAPY BY MONTH 33 RESULTS SUGGEST A PROPORTION OF PATIENTS WITH R/R B-ALL MAY NOT NEED FURTHER THERAPY FOLLOWING TREATMENT WITH OBE-CEL LONDON, JUNE 12, 2025 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), AN EARLY COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, TODAY ANNOUNCES UPDATED LONG TERM DATA (UP TO APPROXIMATELY THREE YEARS OF FOLLOW UP) FROM THE FELIX STUDY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL), TO BE PRESENTED IN AN ORAL PRESENTATION AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) CONGRESS BETWEEN JUNE 12-15, 2025, IN MILAN, ITALY. AUTOLUS WILL ALSO PRESENT AN ADDITIONAL ORAL AND POSTER PRESENTATION, THE DETAILS OF WHICH ARE INCLUDED BELOW.

AUTOLUS THERAPEUTICS PRESENTS LONG-TERM FOLLOW UP FROM THE FELIX STUDY DEMONSTRATING OBE-CEL'S POTENTIAL FOR LONG-TERM REMISSION IN R/R B-ALL AT THE 2025 EUROPEAN HEMATOLOGY ASSOCIATION (EHA) CONGRESS

Autolus Therapeutics plc

AUTL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Autolus Therapeutics plc

AUTL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AUTL